Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03951116 · ClinicalTrials.gov registry record · Phase 1

Study of FCN-437c in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, Adult, sponsored by Fochon Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
3
Study locations

NCT03951116 is a Phase 1 study of Solid Tumor, Adult that has completed, run by Fochon Pharmaceuticals. The registered enrollment target is 22 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03951116, a Phase 1 study of Solid Tumor, Adult, has completed, sponsored by Fochon Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
3
Study locations

Study Summary

This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG FCN-437

Study Locations (3)

California

  • City of Hope National Medical Center - Duarte

Tennessee

  • Sarah Cannon Research Institute at Tennessee Oncology - Nashville

Texas

  • South Texas Accelerated Research Therapeutics (START) - San Antonio

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-06-25
Est. Completion 2021-12-08
Phase Phase 1

Sponsor

Fochon Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03951116

The ClinicalTrials.gov registry entry for NCT03951116 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (88% lower). The listed sponsor is Fochon Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which FCN-437 is the first listed.

NCT03951116 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT03951116 about?

NCT03951116 is a clinical study titled "Study of FCN-437c in Patients With Advanced Solid Tumors". This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

What is the current status of trial NCT03951116?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-06-25. Estimated completion is 2021-12-08.

What conditions does trial NCT03951116 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT03951116?

The interventions under investigation include: FCN-437 (DRUG).

Who is sponsoring clinical trial NCT03951116?

This trial is sponsored by Fochon Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03951116 being conducted?

This trial has 3 study locations across California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.